2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.
17 citations
,
August 2019 in “Archives of Cardiovascular Diseases” In this study, the authors observed that testosterone therapy shortened the QTc interval and normalized T-wave morphology in men with acquired LQTS or TdP linked to hypogonadism, suggesting testosterone may be helpful in treatment.
8 citations
,
February 2021 in “Journal of the American Heart Association” This study observed that medical castration for prostate cancer prolongs the QT/QTc intervals, potentially leading to serious arrhythmias like torsade de pointes and ventricular fibrillation, even in patients without prior QT prolongation risk.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
9 citations
,
March 2019 in “European Journal of Sport Science” This article discusses laboratory and physical markers that may help detect androgenic anabolic steroid abuse in athletes and reports no new primary research results.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.
September 2025 in “Medicine” This study found that male patients with androgenetic alopecia exhibited signs of increased arrhythmia risk, such as higher P-wave dispersion and lower corrected QT interval on ECG, suggesting potential benefits from closer cardiac monitoring.
2 citations
,
January 2018 in “Elsevier eBooks” Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
60 citations
,
July 2018 in “Circulation” This study found that hypogonadism in men can be a reversible risk factor for torsades de pointes (TdP), with testosterone replacement potentially preventing TdP recurrence.
147 citations
,
November 2020 in “Journal of Internal Medicine” This review discusses factors contributing to COVID-19 severity disparities, highlighting age, comorbidities, race/ethnicity, and gender, and reports no new clinical findings; it emphasizes understanding these mechanisms to address risk differences.
1 citations
,
August 2025 in “The Egyptian Journal of Internal Medicine” This paper reviews obesity diagnosis and screening methods, emphasizing BMI's practicality in low- and middle-income countries, but provides no new clinical results.
1 citations
,
April 2017 in “European Psychiatry” This case study describes a patient who developed mild eosinophilia and a skin rash after starting clozapine, which resolved without discontinuing the medication.
3 citations
,
June 2014 in “Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology” This article discusses historical serendipitous discoveries in science and medicine but provides no new research findings.
1 citations
,
February 2024 in “Pharmacognosy Journal” In this study, fenugreek seed extract showed significant androgenic and spermatogenic effects in male rats, likely through inhibiting testosterone metabolism, without impacting cardiovascular health.
1415 citations
,
October 2007 in “European Journal of Epidemiology” This article reviews the objectives and design of the Rotterdam Study and summarizes key findings across its focus on various diseases, without reporting new experimental results.
359 citations
,
September 2017 in “European Journal of Epidemiology” This article discusses the rationale, design, and significant findings of the long-running Rotterdam Study but reports no new clinical results.
336 citations
,
August 2015 in “European Journal of Epidemiology” This article reviews the design and objectives of the Rotterdam Study, as well as summarizes major findings, without reporting new results.
266 citations
,
November 2013 in “European Journal of Epidemiology” This article outlines the rationale and design of the Rotterdam Study, summarizes its major findings, and updates its objectives and methods; it reports no new research results.
247 citations
,
August 2011 in “European Journal of Epidemiology” This article outlines the rationale, design, major findings, and updated objectives of the ongoing Rotterdam Study, without presenting new research data.
219 citations
,
September 2009 in “European journal of epidemiology” This article discusses the rationale, design, major findings, and updated objectives and methods of the ongoing Rotterdam Study on various diseases, without reporting new research results.
64 citations
,
August 2019 in “Circulation” This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.
84 citations
,
August 2023 in “Drugs” This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.
34 citations
,
September 2020 in “BMC Endocrine Disorders” This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.
24 citations
,
December 2009 in “Future Medicinal Chemistry” This study identified new potential targets and indications for several marketed drugs using in silico profiling, suggesting opportunities for drug repositioning.
16 citations
,
November 2020 in “Research Square (Research Square)” In this study, early treatment with nitazoxanide, ivermectin, or hydroxychloroquine, combined with azithromycin, was associated with reduced hospitalizations, respiratory complications, and deaths in early-stage COVID-19 patients compared to untreated controls.
11 citations
,
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” This study observed that early treatment with azithromycin and either nitazoxanide, ivermectin, or hydroxychloroquine in COVID-19 patients may reduce viral shedding, symptom duration, and respiratory complications compared to untreated patients.
6 citations
,
May 2020 in “Pharmacology Research & Perspectives” This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.
1 citations
,
January 2018 in “Side effects of drugs annual” This review in SEDA Volume 40 summarizes new adverse reaction data for diuretics published in 2017, highlighting specific risks such as fractures with loop diuretics and hyperkalemia with spironolactone.